slide 1 slide 2 slide 3 slide 4 slide 5 slide 6
Nanotechnology Solutions for Human Health & Disease

Erik C Dreaden, PhD

Our research focuses on the development & use of nanoscale technologies that synthetically manipulate human biology - as therapy. These include synthetic lethal RNA interference, photo-activated drugs, horizontal cell signal blockade, and de-personalized approaches to cancer chemotherapy.

Read More
RNAi-Based Gene Therapy

RNA interference therapy co-opts a natural process by which cells modulate protein levels through microRNA. By delivering synthetic RNA sequences that mimic mircoRNA - directly into diseased cells - we can selectively silence disease-causing proteins.

De-Personalized Medicine

Cellular heterogeneity within tumors drives resistance to personalized medicines. We are developing nanotechnology-enabled de-personalized approaches to chemotherapy that simultaneously target multiple types of cells within the complex tumor microenvironment.

Horizontal Cell Signal Blockade

Cancer cells exploit redundancy in cell signaling pathways to circumvent therapeutic inhibitors. We are developing nanotechnologies that preemptively block known fail-safe pathways in order to starve tumor cells of oncogene-addicted signaling.

Photo-Activated Drugs

Drugs that activate upon light exposure can improve the safety and tolerability of tissue-targeted drugs. We are designing organic and inorganic nanotechnologies that release drugs or intense heat energy in response to exposure to specific frequencies of laser light.

Welcome to the professional webpage of Dr. Erik C Dreaden.

I am currently an NIH Ruth L Kirschstein Postdoctoral Fellow at MIT working the in the laboratory of Paula T Hammond in the Department of Chemical Engineering. I am housed in the Koch Institute for Integrative Cancer Research in Cambridge, MA. Please read more about our exciting work below!

See More

Image gallery

Read More


A selection of our recent manuscripts.

blog image 4
Nanotech-Enabled Combination Chemotherapy
blog image 1
Systems Pharmacology
blog image 2
Resistance to Nanomedicines
blog image 3
Stoichometric Combination Cancer Therapy
blog image 4
Multimodal Tumor-Targeting
blog image 4
Gold Nanotech in Medicine
blog image 4
Noble Metal Biotechnologies

Our partners

Our work is conducted at MIT and Harvard/Dana-Farber; it is supported by the National Institutes of Health, the Department of Defense, Janssen Pharmaceuticals, and Novartis Pharmaceuticals.

partner 1 partner 2 partner 3 partner 4 partner 5 partner 6 partner 7 partner 8

Our collaborators

Paula T Hammond, PhD has been Erik’s postdoctoral advisor and mentor since 2012. She is Koch Professor of Engineering in the Department of Chemical Engineering at MIT and works closely with him on all current projects.

client image 1

Michael B Yaffe, MD, PhD is Professor of Biology and Biological Engineering at MIT. He works closely with Erik to develop synthetic lethal approaches to drugging DNA damage response using RNAi-based gene therapy.

client image 2

Ronny I Drapkin, MD, PhD is Assistant Professor of Pathology at Harvard Medical School, Principal Investigator in Medical Oncology at the Dana-Farber Cancer Institute, and Associate Pathologist at Brigham and Women's Hospital. He is Co-mentor to Erik as part of his NIH Kirschstein Postdoctoral Fellowship and works with him to develop synergistic drug therapies for advanced ovarian cancers.

client image 3

Curriculum vitae

It appears your Web browser is not configured to display PDF files. No worries, just click here to download the PDF file.


Contact us

Pellentesque aliquam in risus eu ultrices. Suspendisse id interdum nibh. Etiam vel mattis augue, a vestibulum arcu. Nam rutrum diam dolor, eu vehicula nisl tincidunt non. Fusce tincidunt id justo eu tempor. Phasellus sit amet ante lobortis, mattis sapien id, dictum ipsum.
Copyright © 2014 Erik C Dreaden. All rights reserved.